Related Experiment Videos
Pulsed estrogen therapy: relieving climacteric symptoms, preventing postmenopausal bone loss
1Palacios Institute for Women's Health, Madrid, Spain.
Climacteric : the Journal of the International Menopause Society
|December 17, 2002
Summary
Pulsed estrogen therapy, Aerodiol, effectively treats menopausal symptoms like hot flashes and night sweats. It also improves lipid profiles and prevents bone loss, offering a comprehensive solution for estrogen deprivation.
Area of Science:
- Endocrinology
- Pharmacology
- Gynecology
Background:
- Estrogen deprivation leads to climacteric symptoms and long-term health consequences.
- Traditional estrogen therapies have limitations, including hepatic first-pass metabolism.
Purpose of the Study:
- To evaluate the efficacy of Aerodiol, a pulsed estrogen therapy, in managing climacteric symptoms.
- To assess the impact of Aerodiol on lipid profiles, bone turnover, and bone mineral density.
- To compare Aerodiol's effectiveness with oral and transdermal estrogen therapies.
Main Methods:
- Four international studies investigated pulsed estrogen therapy (Aerodiol).
- Climacteric symptoms were assessed individually and using the Kupperman index.
- Lipid profiles, bone turnover markers, and bone mineral density were measured.
Main Results:
- Aerodiol significantly reduced the Kupperman index and menopausal symptoms within two weeks.
- Effective even in highly symptomatic women and smokers.
- Improved lipid profiles by decreasing harmful lipoproteins and cholesterol.
- Normalized bone turnover to premenopausal levels within three months.
- As effective as transdermal patches in increasing bone mineral density.
Conclusions:
- Pulsed estrogen therapy with Aerodiol offers a novel and effective treatment for a wide range of menopausal symptoms.
- It provides significant benefits for lipid profiles and bone health, comparable to existing therapies.
- Aerodiol presents a favorable option for managing estrogen deprivation consequences.